By The Life Science Report – Source: Streetwise Reports   06/15/2020

Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19.

Clinical-stage biopharmaceutical company Edesa Biotech Inc. (EDSA:NASDAQ), which is focused on developing treatments for inflammatory and immune-related diseases, today announced that “it has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients.”

The firm indicated that it a has sufficient EB05 drug product available now and plans to begin the study at up to 30 sites. The company advised that it is also currently seeking government grants to accelerate the commencement and roll out of the study.

The company explained that “EB05 is a monoclonal antibody that has demonstrated the ability to suppress the release of proinflammatory cytokines that are often observed in severe COVID-19 patients and that specifically, the drug inhibits toll-like receptor 4 (TLR4) signaling – a key component of the innate immune system and an important mediator of inflammation responsible for acute lung injury that has been shown to be activated during SARS and Influenza infection.”

The firm stated that it plans to enroll as many as 355 patients in the first phase of the Phase 2/3 EB05 trial, which is planned to be a multi-location study to evaluate the efficacy and safety of EB05 in moderate to severe adult hospitalized COVID-19 patients.

The company’s CEO Dr. Par Nijhawan commented, “Health Canada’s expedited review process and subsequent approval of our Clinical Trial Application represents a significant step in developing new drugs that can treat the underlying conditions induced by the SARS-CoV-2 infection…We greatly appreciate the actions being taken by the government to expedite COVID-19 applications and provide support for clinical studies.”

Edesa Biotech is a clinical-stage biopharmaceutical company based in Markham, Ontario, and also has offices in the U.S. located in southern Calif. The firm develops treatments for inflammatory and immune-related diseases particularly those with clear unmet medical needs.

Edesa Biotech started off the day with a market capitalization of around $25.7 million with approximately 8.859 million shares outstanding. EDSA shares opened 140% higher today at $6.97 (+$4.07, +140.34%) over Friday’s $2.90 closing price. The stock has traded today between $5.80 and $10.00 per share and is currently trading at $6.17 (+$3.27, +112.76%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: EDSA:NASDAQ,
)